Skip to main content

Matthew S. Mora

Associate

[email protected]

+1.202.434.7411

Share:

Matt advises health care clients on regulatory and transactional matters, including fraud and abuse, HIPAA privacy and security, and general contracting.

Prior to joining Mintz, Matt worked as in-house counsel at an independent hospital and outpatient facility, where he provided guidance on a range of fraud and abuse issues, including compliance with the Stark Law, the Anti-Kickback Statute, and the False Claims Act. He also counseled on HIPAA privacy and security as well as other regulatory matters. Matt handled the structuring and negotiation of physician and referral source arrangements, negotiated vendor contracts, and assisted in the formation of a Medicare Shared Savings Program Accountable Care Organization. In addition, Matt conducted due diligence and drafted, negotiated, and finalized complex transactions for the facility. He also regularly provided guidance on corporate governance issues and prepared regulatory and corporate filings.


 Matt received the Health Law Certificate at the University of Maryland ‘s Francis King Carey School of Law and was a law clerk in the Office of the General Counsel at the Johns Hopkins Health System and at the Maryland Department of Health and Mental Hygiene.


* Not admitted to practice in the District of Columbia. Working under the supervision and guidance of members of the Bar of the District of Columbia. Admitted to practice in Maryland only.
 

Education

  • University of Maryland (JD)
  • University of Maryland (BA, cum laude)

Involvement

  • Member, American Health Lawyers Association

Viewpoints

Viewpoint
The Department of Health and Human Services Office of the Inspector General (“OIG”) has issued an Advisory Opinion regarding a surgical device and wound care product manufacturer’s proposal to offer its hospital customers who purchase a suite of three joint replacement products a warranty program covering the Product Suite.
In an attempt to lower drug prices, CMS released a proposed rule last week to reduce payments for new drugs under the Part B program.